A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation

Liver International

Volumn 31, Issue 10, 2011, Pages 1477-1484

  Xu, Xiao ^a,b   Tu, Zhenhua ^a,b   Wang, Bei ^a,b   Ling, Qi ^a,b   Zhang, Lin ^b   Zhou, Lin ^b   Jiang, Guoping ^a,b   Wu, Jian ^a,b   Zheng, Shusen ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Hepatitis B recurrence; Liver transplantation; Model; Related risk factors

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VIRUS DNA; HEPATITIS B(E) ANTIGEN; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; END STAGE LIVER DISEASE; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PROCESS MODEL; RECURRENCE RISK; RECURRENT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; VALIDATION PROCESS; VIRUS GENE; VIRUS MUTATION;

ADULT; DNA, VIRAL; FEMALE; HEPATITIS B; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 80054001195     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02500.x     Document Type: Article

References (41)

1. Zheng SS, Liang TB, Wang WL, et al. Clinical experience in liver transplantation from an organ transplantation center in China. Hepatobiliary Pancreat Dis Int 2002; 1: 487-91.
2. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-20.
3. Zheng SS, Liang TB, Xu X.10-year review of 120 cases of liver transplantation. China J Gen Surg 2003; 18: 71-3.
4. Samuel D, Feray C, Bismuth H.Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol 1997; 12: 335-41.
5. Yue Y, Meng J, Zhang S.Mechanism of peripheral blood mononuclear cell invasion by HBV on artifical immunization in newborns. Chin Med J (Engl) 2002; 115: 1380-2.
6. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-8.
7. Seehofer D, Rayes N, Steinmuller T, et al. Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transpl 2001; 7: 976-82.
8. Lu SC, Yan LN, Li B, et al. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report. Hepatobiliary Pancreat Dis Int 2003; 2: 196-201.
9. Wu LM, Xu X, Zheng SS.Hepatitis B virus reinfection after Liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int 2005; 4: 502-8.
10. Botta F, Giannini E, Romagnoli P, et al. MELD scoring systemis useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52: 134-9.
11. Cabrerizo M, Bartolome J, Carreno V.In vitro infection of human peripheral blood mononuclear cells by a defective hepatitis B virus with a deletion in the PreS1 region of the viral genome. J Viral Hepat 2002; 9: 265-71.
12. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplant 2001; 72: 1381-5.
13. Bui Han SH, Martin P.Liver transplantation. Hepatol Res 2004; 29: 193-201.
14. Samuel D. Managrment of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24: 55-62.
15. Lo CM, Fan ST, Liu CL, et al. Prophylaxis and treatment of recurrence hepatitis B after liver tranplantation. Transplantation 2003; 75: S41-4.
16. Benhamou Y, Bochet M, Thibault V, et al. Safety and efcacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study. Lancet 2001; 358: 718-23.
17. Perillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90.
18. Walsh KM, Woodall T, Lamy P, et al. Successful treatment with ade-fovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001; 49: 436-40.
19. Tillmann HL, Bock CT, Bleck SJ, et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufciency. Liver Transpl 2003; 9: 191-6.
20. Samuel D, Kimmoun E.Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clin Liver Dis 2003; 7: 667-81.
21. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-35.
22. Ben-Ari Z, Daudi N, Klein A, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutation in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151-9.
23. Kim KH, Lee KH, Chang HY, et al. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003; 71: 367-75.
24. Beckebaum S, Malago M, Dirsch O, et al. Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after living donor liver transplantation. Clin Transplant 2003; 17: 554-9.
25. Cooreman MP, Leroux-Roels G, Paulij WP.Vaccine- and hepatitis B immune globulin-induced escape mutation of hepatitis B virus surface antigen. J Biomed Sci 2001; 8: 237-347.
26. Ben-Ari Z, Mor E, Shapira Z, et al. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-7.
27. Malkan G, Cattral MS, Humar A, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69: 1403-7.
28. Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002; 4: 137-3.
29. Ben-Ari Z, Ashur Y, Dandi N, et al. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation. Clin Transplant 2004; 18: 415-22.
30. Zheng SS, Wu J, Wang WL, et al. Lamivudine as prophylaxis against hepatitis B virus reinfection following orthotopic liver transplantation. Chin Med J 2002; 82: 445-8.
31. Bramhall SR, Minford B, Gunson B, et al. Liver transplantation in the UK. World J Gastroenterol 2001; 7: 602-11.
32. Roche B, Samuel D.Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-85.
33. Prieto M, Aguilera V, Berenguer M.Hepatitis B prophylaxis following liver transplantation and treatment of recurrence. Gastroenterol Hepatol 2006; 2: 65-71.
34. Lu AW, Zheng SS, Wu MP, et al. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 357-61.
35. Angus PW, Patterson SJ, Strasser SI, et al. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.
36. Yi NJ, Suh KS, Cho JY, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-8.
37. Mazzaferro V, Regalia E, Montalto F, et al. Risk of HBV reinfection after liver transplantation in HBsAg-positive cirrhosis. Primary hepatocellular carcinoma is not a predictor for HBV recurrence. The European Cooperative Study Group on Liver Cancer and Transplantation. Liver 1996; 16: 117-22.
38. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 2008; 134: 1890-9.
39. Kiyici M, Yilmaz M, Akyildiz M, et al. Association between hepatitis B and hepatocellular carcinoma recurrence in patients undergoing liver transplantation. Transplant 2008; 40: 1511-7.
40. Lagget M, Rizzetto M.Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2003; 4: 1821-7.
41. Trotter JF, Wachs M, Everson GT, Kam I.Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002; 346: 1074-82.